AstraZeneca Refocuses On Risk Management, Elevates Development Oversight
This article was originally published in The Pink Sheet Daily
Executive Summary
Former Exec VP-Product Strategy & Licensing John Patterson will assume the board-level position of exec director-development effective Jan. 1. Regulatory affairs overhaul will include a review of ongoing Phase III programs for Galida, Cerovive and Symbicort.
You may also be interested in...
AstraZeneca Files NDA For Symbicort Asthma Therapy
Company has discussed potential delays in review of the metered dose inhaler asthma product.
AstraZeneca Files NDA For Symbicort Asthma Therapy
Company has discussed potential delays in review of the metered dose inhaler asthma product.
Symbicort NDA On-Track Despite FDA Data Request, AstraZeneca Says
FDA has requested additional chemistry, manufacturing and control data for Symbicort inhalation delivery device. While AstraZeneca does not believe this will significantly delay product development, the company does have a back-up strategy for a slightly modified device.